Logo image of KYTX

KYVERNA THERAPEUTICS INC (KYTX) Stock Fundamental Analysis

NASDAQ:KYTX - Nasdaq - US5019761049 - Common Stock - Currency: USD

2.91  -0.05 (-1.69%)

After market: 3.05 +0.14 (+4.81%)

Fundamental Rating

1

Overall KYTX gets a fundamental rating of 1 out of 10. We evaluated KYTX against 557 industry peers in the Biotechnology industry. While KYTX seems to be doing ok healthwise, there are quite some concerns on its profitability. KYTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KYTX has reported negative net income.
KYTX had a negative operating cash flow in the past year.
KYTX Yearly Net Income VS EBIT VS OCF VS FCFKYTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -50M -100M

1.2 Ratios

KYTX has a Return On Assets (-55.87%) which is in line with its industry peers.
KYTX has a Return On Equity (-65.00%) which is in line with its industry peers.
Industry RankSector Rank
ROA -55.87%
ROE -65%
ROIC N/A
ROA(3y)-55.05%
ROA(5y)N/A
ROE(3y)-77.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KYTX Yearly ROA, ROE, ROICKYTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

KYTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KYTX Yearly Profit, Operating, Gross MarginsKYTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, KYTX has more shares outstanding
Compared to 1 year ago, KYTX has an improved debt to assets ratio.
KYTX Yearly Shares OutstandingKYTX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M
KYTX Yearly Total Debt VS Total AssetsKYTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

KYTX has an Altman-Z score of -0.60. This is a bad value and indicates that KYTX is not financially healthy and even has some risk of bankruptcy.
KYTX has a better Altman-Z score (-0.60) than 61.22% of its industry peers.
KYTX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
KYTX has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: KYTX outperforms 47.94% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.6
ROIC/WACCN/A
WACCN/A
KYTX Yearly LT Debt VS Equity VS FCFKYTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

KYTX has a Current Ratio of 7.44. This indicates that KYTX is financially healthy and has no problem in meeting its short term obligations.
KYTX has a Current ratio of 7.44. This is in the better half of the industry: KYTX outperforms 67.68% of its industry peers.
A Quick Ratio of 7.44 indicates that KYTX has no problem at all paying its short term obligations.
The Quick ratio of KYTX (7.44) is better than 68.22% of its industry peers.
Industry RankSector Rank
Current Ratio 7.44
Quick Ratio 7.44
KYTX Yearly Current Assets VS Current LiabilitesKYTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

0

3. Growth

3.1 Past

KYTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -137.84%.
EPS 1Y (TTM)-137.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.04%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

KYTX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.65% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-14.49%
EPS Next 2Y3.67%
EPS Next 3Y-7.6%
EPS Next 5Y0.65%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KYTX Yearly Revenue VS EstimatesKYTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
KYTX Yearly EPS VS EstimatesKYTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KYTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KYTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KYTX Price Earnings VS Forward Price EarningsKYTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KYTX Per share dataKYTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

KYTX's earnings are expected to decrease with -7.60% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.67%
EPS Next 3Y-7.6%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KYTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KYVERNA THERAPEUTICS INC

NASDAQ:KYTX (6/18/2025, 4:35:28 PM)

After market: 3.05 +0.14 (+4.81%)

2.91

-0.05 (-1.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11
Inst Owners78.05%
Inst Owner Change-9.92%
Ins Owners1.39%
Ins Owner Change2.88%
Market Cap125.77M
Analysts83.33
Price Target17.54 (502.75%)
Short Float %4.95%
Short Ratio6.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.17%
Min EPS beat(2)-2.95%
Max EPS beat(2)9.3%
EPS beat(4)3
Avg EPS beat(4)3.19%
Min EPS beat(4)-2.95%
Max EPS beat(4)9.3%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.18%
PT rev (3m)-20.37%
EPS NQ rev (1m)-2.02%
EPS NQ rev (3m)-15.9%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.79%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-3.38
EYN/A
EPS(NY)-3.21
Fwd EYN/A
FCF(TTM)-3.12
FCFYN/A
OCF(TTM)-3.08
OCFYN/A
SpS0
BVpS5.18
TBVpS5.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -55.87%
ROE -65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.05%
ROA(5y)N/A
ROE(3y)-77.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.3%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.44
Quick Ratio 7.44
Altman-Z -0.6
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)70.94%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-137.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.04%
EPS Next Y-14.49%
EPS Next 2Y3.67%
EPS Next 3Y-7.6%
EPS Next 5Y0.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-129.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.27%
EBIT Next 3Y-25.97%
EBIT Next 5YN/A
FCF growth 1Y-119.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-117.99%
OCF growth 3YN/A
OCF growth 5YN/A